Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$94.60 USD

94.60
423,408

-0.65 (-0.68%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $94.55 -0.05 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NextGen (NXGN) Announces Positive Telehealth Survey Results

by Zacks Equity Research

NextGen's (NXGN) recent survey indicates growing preference for telehealth services.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.

HCA Healthcare (HCA) to Rebrand Certain Units in Florida

by Zacks Equity Research

HCA Healthcare (HCA) to adopt the HCA Florida Healthcare brand to enhance its appeal and solidify its presence.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

CVS Health (CVS) Launches Clinical Trial Services Business

by Zacks Equity Research

The latest clinical trial experience from CVS Health (CVS) is expected to overcome multiple challenges posed by its current clinical trial model.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.

PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study

by Zacks Equity Research

PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.

Here's Why You Should Retain Ecolab (ECL) Stock Right Now

by Zacks Equity Research

Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness remains a woe.

Veeva Systems' (VEEV) Cloud Offerings Aid Drug Development

by Zacks Equity Research

Veeva Systems' (VEEV) Cloud applications help in simplifying and accelerating drug development on an industry-wide basis.

Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Ecolab (ECL) Launches Roach Control Device for Food Outlets

by Zacks Equity Research

Ecolab's (ECL) latest device is expected to help the restaurant industry efficiently protect their brand reputation and eliminate any business and public health risk.

LHC Group (LHCG) Forays Into Tucson Market With New Buyout

by Zacks Equity Research

LHC Group (LHCG) agrees to buy two Casa de la Luz provider locations to expand its hospice service in the Tucson market.

    Here's Why You Should Invest in Integer Holdings (ITGR) Stock

    by Zacks Equity Research

    Integer Holdings (ITGR) continues to gain traction from portfolio management.

    NextGen (NXGN) Implements API to Aid COVID-19 Vaccination

    by Zacks Equity Research

    NextGen's (NXGN) API is expected to address the unique and evolving reporting needs of various states as they administer the COVID-19 vaccine.

    DVA vs. AMED: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    DVA vs. AMED: Which Stock Is the Better Value Option?

    Orthofix (OFIX) Launches OSCAR PRO System in the US & Europe

    by Zacks Equity Research

    Orthofix's (OFIX) latest innovation is expected to drive organic growth in its Global Orthopedics business.

    PerkinElmer (PKI) to Boost Immunodiagnostics Unit With Buyout

    by Zacks Equity Research

    PerkinElmer (PKI) enters into an agreement to acquire IDS, which will enable the former to grow its overall Diagnostics business, particularly its immunodiagnostics unit.

    QIAGEN (QGEN) Gains from FDA's EUA for Antibody Total Test

    by Zacks Equity Research

    QIAGEN's (QGEN) COVID-19 total antibody test processes up to 32 swab samples per hour.

    Here's Why You Should Add Inogen (INGN) to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.

    BD's (BDX) First Self-Collection HPV Screening Assay Gets CE Mark

    by Zacks Equity Research

    BD's (BDX) industry-first CE marked self-collection claim for HPV screening enables greater access to testing for women.

    HCA Healthcare (HCA) to Divest Hospital for Better Liquidity

    by Zacks Equity Research

    HCA Healthcare (HCA) to sell Redmond Regional Medical Center, GA to AdventHealth for boosting financial solvency.

    PRA Health's (PRAH) New Solution to Speed Up Drug Development

    by Zacks Equity Research

    PRA Health's (PRAH) tokenization solution can help in the generation of enhanced evidence for drug development through Synoma.

    Here's Why You Should Retain Change Healthcare (CHNG) Stock

    by Zacks Equity Research

    Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.

    Here's Why You Should Add Bruker (BRKR) to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.